Clearside Biomedical Beheer
Beheer criteriumcontroles 2/4
Clearside Biomedical's CEO is George Lasezkay, appointed in Apr 2019, has a tenure of 5.58 years. total yearly compensation is $1.54M, comprised of 35.6% salary and 64.4% bonuses, including company stock and options. directly owns 0.51% of the company’s shares, worth $386.59K. The average tenure of the management team and the board of directors is 2.3 years and 5.4 years respectively.
Belangrijke informatie
George Lasezkay
Algemeen directeur
US$1.5m
Totale compensatie
Percentage CEO-salaris | 35.6% |
Dienstverband CEO | 5.6yrs |
Eigendom CEO | 0.5% |
Management gemiddelde ambtstermijn | 2.3yrs |
Gemiddelde ambtstermijn bestuur | 5.4yrs |
Recente managementupdates
Recent updates
Here's Why We're Watching Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 06We're Keeping An Eye On Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Rate
Jun 24Here's Why We're Not At All Concerned With Clearside Biomedical's (NASDAQ:CLSD) Cash Burn Situation
Nov 12Analyst Forecasts Just Became More Bearish On Clearside Biomedical, Inc. (NASDAQ:CLSD)
Aug 11Clearside Biomedical Q2 2022 Earnings Preview
Aug 08Clearside Biomedical: A Pivotal 2022 Ahead
Apr 13Clearside's Safety Data In Wet AMD And Emphasis On SCS Microinjector Make It Great Speculative Play
Dec 22Clearside Biomedical (NASDAQ:CLSD) Is In A Strong Position To Grow Its Business
Sep 30Clearside's Value Proposition Is Far From Clear
Aug 07We Think Clearside Biomedical (NASDAQ:CLSD) Can Easily Afford To Drive Business Growth
Jun 17Clearside Biomedical climbs after positive results from early-stage wet AMD trial
Jun 15Clearside Biomedical resubmits eye treatment XIPERE NDA
May 03If You Had Bought Clearside Biomedical (NASDAQ:CLSD) Shares A Year Ago You'd Have Earned 45% Returns
Feb 16Analyse CEO-vergoeding
Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
---|---|---|---|
Jun 30 2024 | n/a | n/a | -US$33m |
Mar 31 2024 | n/a | n/a | -US$35m |
Dec 31 2023 | US$2m | US$547k | -US$32m |
Sep 30 2023 | n/a | n/a | -US$37m |
Jun 30 2023 | n/a | n/a | -US$36m |
Mar 31 2023 | n/a | n/a | -US$35m |
Dec 31 2022 | US$2m | US$532k | -US$33m |
Sep 30 2022 | n/a | n/a | -US$5m |
Jun 30 2022 | n/a | n/a | -US$2m |
Mar 31 2022 | n/a | n/a | US$83k |
Dec 31 2021 | US$2m | US$516k | US$376k |
Sep 30 2021 | n/a | n/a | -US$25m |
Jun 30 2021 | n/a | n/a | -US$23m |
Mar 31 2021 | n/a | n/a | -US$23m |
Dec 31 2020 | US$1m | US$503k | -US$18m |
Sep 30 2020 | n/a | n/a | -US$14m |
Jun 30 2020 | n/a | n/a | -US$18m |
Mar 31 2020 | n/a | n/a | -US$18m |
Dec 31 2019 | US$1m | US$385k | -US$31m |
Sep 30 2019 | n/a | n/a | -US$49m |
Jun 30 2019 | n/a | n/a | -US$67m |
Mar 31 2019 | n/a | n/a | -US$82m |
Dec 31 2018 | US$150k | n/a | -US$83m |
Sep 30 2018 | n/a | n/a | -US$78m |
Jun 30 2018 | n/a | n/a | -US$72m |
Mar 31 2018 | n/a | n/a | -US$65m |
Dec 31 2017 | US$167k | n/a | -US$59m |
Compensatie versus markt: George's total compensation ($USD1.54M) is above average for companies of similar size in the US market ($USD655.65K).
Compensatie versus inkomsten: George's compensation has increased whilst the company is unprofitable.
CEO
George Lasezkay (72 yo)
5.6yrs
Tenure
US$1,538,627
Compensatie
Dr. George M. Lasezkay, Pharm D, & J.D. has been Chief Executive Officer at Clearside BioMedical, Inc. since March 2020, serves as President since March 1, 2020 and served as its Interim Chief Executive Of...
Leiderschapsteam
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
President | 5.6yrs | US$1.54m | 0.51% $ 386.6k | |
Chief Financial Officer | 12.8yrs | US$854.41k | 0.45% $ 340.8k | |
Head of Investor Relations | no data | geen gegevens | geen gegevens | |
Senior Vice President of Corporate Development & Alliance Management | 2.2yrs | geen gegevens | geen gegevens | |
Senior Vice President of Engineering & Manufacturing | 1.8yrs | geen gegevens | geen gegevens | |
Chief Clinical Officer | 2.4yrs | geen gegevens | geen gegevens | |
Chief Medical Officer | less than a year | geen gegevens | 0.085% $ 64.1k | |
Secretary | no data | geen gegevens | geen gegevens |
2.3yrs
Gemiddelde duur
59yo
Gemiddelde leeftijd
Ervaren management: CLSD's management team is considered experienced (2.3 years average tenure).
Bestuursleden
Naam | Positie | Tenure | Compensatie | Eigendom |
---|---|---|---|---|
President | 7.3yrs | US$1.54m | 0.51% $ 386.6k | |
Independent Director | 12.8yrs | US$86.08k | 0.0059% $ 4.4k | |
Independent Director | 2.7yrs | US$88.58k | 0.024% $ 18.1k | |
Independent Director | 6.2yrs | US$88.58k | 0% $ 0 | |
Independent Chair of the Board | 12.8yrs | US$96.08k | 0.054% $ 40.9k | |
Member of Scientific Advisory Board | 4.6yrs | geen gegevens | geen gegevens | |
Independent Director | 12.8yrs | US$91.71k | 0.068% $ 51.5k | |
Member of Scientific Advisory Board | 4.6yrs | geen gegevens | geen gegevens | |
Independent Director | 4.6yrs | US$85.46k | 0.12% $ 93.9k | |
Independent Director | 8.8yrs | US$91.08k | 0% $ 0 | |
Member of Scientific Advisory Board | 1.6yrs | geen gegevens | geen gegevens | |
Member of Scientific Advisory Board | 1.6yrs | geen gegevens | geen gegevens |
5.4yrs
Gemiddelde duur
64.5yo
Gemiddelde leeftijd
Ervaren bestuur: CLSD's board of directors are considered experienced (5.4 years average tenure).